Business

Medical Developments International (MVP) announced that Mundipharma has acquired exclusive Australian distribution rights for the Penthrox methoxyflurane inhaler. Mundipharma already has the rights to market Penthrox in most of Europe. Mundipharma Australia and New Zealand… Read more . . .

Nasal drug delivery specialist Kurve Technology announced that the US Department of Defense (DoD) has awarded the company a contract for testing a formulation for the treatment of traumatic brain injury (TBI). The Kurve ViaNase… Read more . . .

Acerus Pharmaceuticals said that it has acquired exclusive worldwide rights to technology related to intranasal delivery of testosterone from the University of Texas at Austin. The company said that the agreement covers the use of… Read more . . .

Insmed Incorporated said that a just-closed public stock offering generated net proceeds of about $235.5 million that will be used for continuing commercialization of Arikayce amikacin liposome inhalation suspension (ALIS). The offering of 9,615,385 shares of… Read more . . .

MannKind Corporation has announced that signed a marketing and distribution agreement with Australasian Medical & Scientific Ltd division AMSL Diabetes for commercialization of Afrezza inhaled insulin in Australia. AMSL Diabetes will take responsibility for getting… Read more . . .

Pneuma Respiratory has announced a licensing agreement with Nanjing Leads Biolabs subsidiary Leads Biolabs, Inc. for rights to develop Leads monoclonal antibodies and fusion protein molecules for delivery using Pneuma’s digital soft mist inhaler. Pneuma… Read more . . .

Etripamil developer Milestone Pharmaceuticals announced that its recently closed initial public offering raised approximately $82.5 million gross by selling 5,500,000 common shares at $15/share.  The company is developing intranasal etripamil for the treatment of paroxysmal… Read more . . .